DATE: 03 Nov 2022
CATEGORY: PRESS RELEASE
Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting
Four presentations on three oncology assets, including an oral session on ISB 2001, Ichnos’ first TREATTM trispecific (BCMAxCD38xCD3) antibody
FOR IMMEDIATE RELEASE
NEW YORK, NY
November 03, 2022
NEW YORK, NY, November 3, 2022 – Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, today announced that four abstracts highlighting data on its pipeline assets have been selected for presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 10-13, 2022, in New Orleans, Louisiana.
These abstracts discuss three assets – ISB 1342, ISB 1442 and ISB 2001 – two of which are currently in Phase 1 clinical studies in relapsed/refractory multiple myeloma. The data to be presented will highlight the potential of the company’s proprietary BEAT® platform1 and its growing momentum toward providing curative therapies that may extend and improve lives.
“Our work is grounded in the notion that cure is possible and the understanding that there is room for novel thinking in the pursuit of effective, disease-centric therapies for oncology,” said Cyril Konto, M.D., President and Chief Executive Officer of Ichnos Sciences. “Ichnos is focused on harnessing the power of the immune system in the fight against cancer, and we are pleased to have been selected to present data supporting this approach at the ASH Annual Meeting.”
More information about the presentations is detailed below:
ASH 2022 Presentations
| Title | Details (all times in Central Time) |
|---|---|
| Oral Presentation: ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two Antigens | Saturday, December 10, 2022, 4:00 – 5:30 p.m. Presentation Time: 5:00 p.m. Ernest N. Morial Convention Center, New Orleans Theater C Session: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Publication Number: 353 |
| Poster Presentation: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) | Sunday, December 11, 2022, 6:00 – 8:00 p.m. Ernest N. Morial Convention Center, Hall D Session: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II Publication Number: 3233 |
| Poster Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL | Sunday, December 11, 2022, 6:00 – 8:00 p.m. Ernest N. Morial Convention Center, Hall D Session: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II Publication Number: 2775 |
| Poster Presentation: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma | Monday, December 12, 2022, 6:00 PM – 8:00 p.m. Ernest N. Morial Convention Center, Hall D Session: Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II Publication Number: 4571 |
Visit the Ichnos Sciences booth (#3127) to learn more about Ichnos’ proprietary BEAT platform, expanding pipeline of oncology assets, partnership opportunities and more.
Follow Ichnos on LinkedIn for more updates throughout the conference.
1 BEAT®: Bispecific Engagement by Antibodies based on the TCR
About Ichnos Sciences Inc.
A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT® technology platform and pioneering teams, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.
For more information, visit IchnosSciences.com.
C O N T A C T
Grace Maguire
Head of Communications and Corporate Affairs
Ichnos Sciences
Corporate.Communications@ichnossciences.com